ZA201906696B - Liquid formulation of anti-tnf alpha antibody - Google Patents

Liquid formulation of anti-tnf alpha antibody

Info

Publication number
ZA201906696B
ZA201906696B ZA2019/06696A ZA201906696A ZA201906696B ZA 201906696 B ZA201906696 B ZA 201906696B ZA 2019/06696 A ZA2019/06696 A ZA 2019/06696A ZA 201906696 A ZA201906696 A ZA 201906696A ZA 201906696 B ZA201906696 B ZA 201906696B
Authority
ZA
South Africa
Prior art keywords
liquid formulation
tnf alpha
alpha antibody
antibody
tnf
Prior art date
Application number
ZA2019/06696A
Other languages
English (en)
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201906696(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of ZA201906696B publication Critical patent/ZA201906696B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
ZA2019/06696A 2017-03-16 2019-10-10 Liquid formulation of anti-tnf alpha antibody ZA201906696B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (ko) 2017-03-16 2018-03-16 항-tnf 알파 항체의 액상 제제

Publications (1)

Publication Number Publication Date
ZA201906696B true ZA201906696B (en) 2020-08-26

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/06696A ZA201906696B (en) 2017-03-16 2019-10-10 Liquid formulation of anti-tnf alpha antibody

Country Status (15)

Country Link
JP (2) JP7109849B2 (zh)
KR (2) KR20180106974A (zh)
CN (1) CN110621303A (zh)
AU (1) AU2018236651B2 (zh)
BR (1) BR112019019162A2 (zh)
CO (1) CO2019010860A2 (zh)
MA (1) MA46988A1 (zh)
MX (1) MX2019010895A (zh)
MY (1) MY197202A (zh)
NZ (1) NZ757965A (zh)
PH (1) PH12019502075A1 (zh)
RU (1) RU2756619C2 (zh)
UA (1) UA123847C2 (zh)
WO (1) WO2018169348A1 (zh)
ZA (1) ZA201906696B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474360A (zh) * 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105854016A (zh) * 2010-11-11 2016-08-17 艾伯维生物技术有限公司 改进的高浓度抗TNFα抗体液体制剂
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP3912639A1 (en) * 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
EA201791717A1 (ru) * 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
US20150274819A1 (en) * 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
US10688187B2 (en) * 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
HUE029849T2 (en) * 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
AR103544A1 (es) * 2015-01-28 2017-05-17 Mabxience S A FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
JP2022097600A (ja) 2022-06-30
JP2020510079A (ja) 2020-04-02
AU2018236651B2 (en) 2020-12-10
KR20200096472A (ko) 2020-08-12
CN110621303A (zh) 2019-12-27
JP7109849B2 (ja) 2022-08-01
RU2019130728A (ru) 2021-04-16
RU2756619C2 (ru) 2021-10-04
MA46988A1 (fr) 2020-06-30
PH12019502075A1 (en) 2020-09-14
MY197202A (en) 2023-05-31
MX2019010895A (es) 2019-11-05
CO2019010860A2 (es) 2020-01-17
WO2018169348A1 (ko) 2018-09-20
KR20180106974A (ko) 2018-10-01
RU2019130728A3 (zh) 2021-04-16
AU2018236651A1 (en) 2019-10-31
UA123847C2 (uk) 2021-06-09
KR102342292B1 (ko) 2021-12-24
NZ757965A (en) 2022-07-01
BR112019019162A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
IL282962A (en) Anti-PD-1 antibodies and methods of using them
HK1244492A1 (zh) 抗pd-1抗體及其使用方法
CL2016003250A1 (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
HUE062927T2 (hu) Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
HUE062436T2 (hu) Anti-trem2 antitestek és alkalmazási módszereik
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
SG11201706505PA (en) Stable liquid formulation for monoclonal antibodies
HK1251969A1 (zh) 抗her2抗體和使用方法
HK1254743A1 (zh) 新穎抗密封蛋白抗體及使用方法
HK1259251A1 (zh) 人源化抗c1s抗體及其使用方法
IL286208A (en) Monoclonal antibodies of human origin and methods of using them
IL268731A (en) New uses of anti-SIRPG antibodies
EP3394098A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
IL265438A (en) Chimeric antigen receptors and jewelry and methods of using them
PL3110447T3 (pl) Przeciwciało anty-EGFR i jego zastosowania
SG11202001720RA (en) Liquid dosage forms of imatinib
PL3544416T3 (pl) Nanoszenie cieczy
ZA201906696B (en) Liquid formulation of anti-tnf alpha antibody
ZA201805051B (en) Egfl6 specific monoclonal antibodies and methods of their use
GB2548424B (en) Liquid pharmaceutical composition of clonidine